HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

8th Edition of World Congress on Infectious Diseases

June 09-11, 2025 | Rome, Italy

June 09 -11, 2025 | Rome, Italy
Infection 2024

Incremental value of an ultra rapid phenotypic antimicrobial susceptibility testing in patients with bloodstream infection: A modeling approach

Speaker at Infectious Diseases Conferences - Filipa de Aragao
Incremental Action Consulting Lda, Portugal
Title : Incremental value of an ultra rapid phenotypic antimicrobial susceptibility testing in patients with bloodstream infection: A modeling approach


Background and Goal: When bloodstream infection (BSI) is suspected, empirical broad-spectrum antimicrobial treatment (AMT) is immediately initiated after sampling for blood cultures. In the context of an increasing rate of multidrug-resistant organisms, rapid microbiological investigations—identification of the causative agent and antimicrobial susceptibility testing (AST) – are key to minimize time on inappropriate therapy, to limit the selection of resistant strains and to limit AMT-associated toxicity. This study aimed to quantify the health and economic gains achievable by replacing the current standard of care (SoC) with an ultra-rapid AST directly performed from blood cultures.

Methods: A decision-tree model was developed to compare between SoC (isolation in culture medium + MALDI-TOF-MS + VITEK 2 AST), which has a time to results (TTR) of 51 hours(h), rapid ASTs (5h<TTR<8h), and FASTinov ultra-rapid (UR) AST (TTR=2h), in hospitalized patients with BSI. Outcomes of interest were mortality, hospital length of stay (LoS) and costs. Outcomes were linked to TTR through the duration of inappropriate therapy. Inputs were based on the literature. Conservatively, due to lack of evidence, AST TTR was assumed not to impact outcomes in patients initiating appropriate empirical therapy. A time-horizon of 30 days was considered, and the payer perspective was adopted.

Results: The 2h TTR UR-AST test allows for decision-making in the same medical shift, while rapid ASTs likely yield next day intervention, and SoC requires at least 3 days to achieve AST based optimized regimen. In that context, in the overall BSI patient population, replacing current SoC with FASTinov UR-AST allows reductions of 8.0% in mortality (12.4% vs 13.5%), 30.1% in LoS (6.7 vs 9.6 days) and 28.0% in costs (6,148€ vs 8,542€)When comparing the 2h TTR UR-AST to rapid ASTs, the benefit is estimated to result in a reduction of 8.0% in mortality, 15.7% in LoS (6.7 vs 7.9 days) and 14.3% in costs (6,148€ vs 7,177€)..

Conclusion: Availability of AST results on the same medical shift reduces mortality, LoS and costs of hospitalized patients with BSI.


Filipa is a researcher at Nova University Public Health Research Centre and a founding partner at Incremental Action Consulting, Lda (INCA), with strong experience health economics and outcomes research (HEOR) data generation, acquired through a solid academic background followed by 25+ years working in Health Economics. Filipa is highly proficient in model design and optimization for maximum product differentiation across markets. Before setting up her company, Filipa was the HEOR lead for the European Region at Gilead Sciences Inc. Filipa has a PhD in Public Health and Health Economics, a post-graduation in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine. She is a FullBright scholar and a Fundação para a Ciência e a Tecnologia scholar, among others.